27978 Psoriasis and methotrexate: A systematic review and meta-analysis of nonmelanoma skin cancer risk
Background: Psoriasis is a chronic, autoimmune dermatologic disease that often requires systemic treatment. Of the immune regulating therapies, methotrexate (MTX) is a commonly used systemic therapy. Both MTX and psoriasis are associated with an increased risk of developing nonmelanoma skin cancers (NMSCs). Currently, the risk associated with combining these factors is not well quantified.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Margaret E. Lang, Jacob Stewart, Patricia J. Erwin, Jerry D. Brewer Source Type: research
More News: Academies | Autoimmune Disease | Cancer | Cancer & Oncology | Dermatology | Methotrexate | Nonmelanoma Skin Cancer | Psoriasis | Skin | Skin Cancer